Enabling mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency

Codex^® HiCap RNA Polymerase addresses challenges to drive advancement in IVT

As growth in the mRNA therapeutics and vaccines space intensifies, regulatory bodies are placing increasing scrutiny on standards for quality, manufacture and purity. The 5’ cap is essential for activating and stabilizing the transcript, and uncapped species can increase immunogenicity.

Codex HiCap Polymerase is a uniquely engineered RNA polymerase that enables researchers to produce synthetic capped mRNA at the high yield and purity that today’s mRNA-based vaccines and therapeutics demand. It incorporates commercially available cap analogs more efficiently by co-transcriptional capping, producing in vitro transcription (IVT) products with unparalleled efficiency.

This paper explores the different approaches for capping in IVT, and presents data demonstrating how Codex HiCap RNA Polymerase can help deliver safer and more potent therapeutic mRNAs while creating efficiencies to reduce the costs of your clinical development

Download this whitepaper to learn how Codex HiCap RNA Polymerase can help enhance therapeutic mRNA safety and potency while optimizing efficiency to lower clinical development costs.